EXEL. Negatives for me: Stock seems expensive: it's been on an upward trajectory and is near an all-time high. (For you, bruwin, with a TA view and rising support levels, that may be a positive.) For me, the high price compared to its history is a concern.
I’ve no knowledge of the business aspects of this company. How good is their major drug; do they have a pipeline; what's the durability; who are the competitors, etc.?
OTOH, company has little ltd, profit margins are high. If analysts are correct and earnings in ’26 are about $2.7+ , and if still outlooked even higher in ’27, then I could see the stock selling next year at about 25x $2.7, or about $68/sh., up from today’s $44.
I’ll say risky, but for me ok to buy just a few tracking shares. I'll have it in a small basket of biotech/drug stocks where I've not much conviction in any, but I'm willing to bet a few bucks that overall the winners (if there are any) will outperform the losers I might have over a two year period I might have them. |
